Journal of Infectious Diseases and Medical Microbiology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Opinion Article - Journal of Infectious Diseases and Medical Microbiology (2025) Volume 9, Issue 1

Infections in Immunocompromised Hosts: Challenges and Management

Hoban Murtaza*

SupAgro, UMR CBGP, Montferrier-sur-Lez, France

*Corresponding Author:
Hoban Murtaza
SupAgro, UMR CBGP, Montferrier-sur-Lez, France
E-mail: murta.hoban@supagro.inra.fr

Received: : 01-Jan-2025, Manuscript No. AAJIDMM - 25-161882; Editor assigned: 05-Jan-2025, PreQC No. AAJIDMM - 25-161882 (PQ); Reviewed: 19-Jan-2025, QC No. AAJIDMM - 25-161882; Revised:22-Jan-2025, Manuscript No. AAJIDMM - 25-161882 (R); Published:29-Jan-2025, DOI:10.35841/10.35841/ aajidmm-9.1.247

Citation: Citation: Murtaza H. Infections in Immunocompromised Hosts: Challenges and Management. J Infect Dis Med Microbiol. 2025; 9(1):247

Abstract

  

Introduction

Immunocompromised individuals are at a heightened risk for infections due to a weakened or impaired immune system. This can be the result of various conditions, including autoimmune diseases, cancer, HIV/AIDS, organ transplantation, or the use of immunosuppressive drugs. [

When the immune system is compromised, the body's ability to fight off pathogens— such as bacteria, viruses, fungi, and parasites—becomes significantly diminished, leaving these individuals vulnerable to severe and often life-threatening infections. Understanding the mechanisms behind infections in immunocompromised hosts, the types of pathogens involved, and the strategies for prevention and management is essential to improving outcomes in this population. In this article, we will explore the challenges faced by immunocompromised individuals in terms of infection risk, the types of infections they are particularly susceptible to, and current strategies for management and prevention. [2, 3].

These are genetic disorders where the immune system is inherently weak or absent. Severe combined immunodeficiency (SCID),Common variable immunodeficiency (CVID),Xlinked agammaglobulinemic (XLA)These conditions lead to an increased susceptibility to bacterial, viral, and fungal infections early in life [4].

Secondary immune deficiencies are acquired conditions that weaken the immune system. Common causes include: The human immunodeficiency virus (HIV) targets and destroys CD4+ T cells, which are critical to the immune response, leading to a progressive loss of immune function. Without treatment, HIV can progress to AIDS (acquired immunodeficiency syndrome), where the body becomes highly susceptible to opportunistic infections. Chemotherapy, radiation therapy, and certain cancers (e.g., leukemia, lymphoma) directly compromise immune function, leading to neutropenia (low white blood cell count) and increased susceptibility to infections. [5, 6].

Immunocompromised patients may present with atypical or milder symptoms due to their impaired immune response, leading to delays in diagnosis. Infections may progress to severe or systemic involvement before they are recognized. Many antibiotics, antivirals, and antifungals are less effective or require higher doses in immunocompromised individuals due to altered pharmacokinetics or pharmacodynamics [7].

Additionally, the risk of drug interactions and adverse effects from polypharmacy (the use of multiple medications) complicates treatment plans. The overuse and misuse of antimicrobial agents, particularly in hospitals, can lead to the development of multidrug-resistant (MDR) pathogens. Immunocompromised patients are at higher risk of acquiring these resistant infections, which are harder to treat and associated with worse outcomes. Immunocompromised individuals are more likely to develop opportunistic infections caused by normally harmless organisms that take advantage of the weakened immune system. These infections may be difficult to treat and may require prolonged courses of therapy. [8].

Preventing and managing infections in immunocompromised hosts requires a comprehensive, multidisciplinary approach: Immunocompromised individuals should receive appropriate vaccines, such as the pneumococcal vaccine, influenza vaccine, and hepatitis vaccines [9].

However, live vaccines should generally be avoided, particularly in those on immunosuppressive therapy. Many immunocompromised patients, particularly those undergoing chemotherapy or organ transplantation, are given prophylactic antibiotics, antivirals, or antifungals to prevent infections, such as Pneumocystis jirovecii pneumonia (PCP) in HIV patients. Immunocompromised individuals should be advised to avoid exposure to infectious agents, including avoiding crowded places, practicing good hygiene, and using insect repellent to prevent vector-borne diseases. [10].

conclusion

Infections in immunocompromised hosts represent a significant and growing challenge in modern medicine. Whether due to primary immune deficiencies, secondary conditions such as cancer or HIV/AIDS, or the use of immunosuppressive therapies, individuals with weakened immune systems are particularly vulnerable to a wide array of pathogens. Early diagnosis, aggressive management, and preventive strategies such as vaccination and prophylactic treatments are essential for improving outcomes and reducing the risk of severe infections. As medical advancements continue to improve, there is hope that better treatments, vaccines, and preventative strategies will help mitigate the risks faced by immunocompromised patients, ultimately enhancing their quality of life and survival rates.

References

  1. Rocha AF, Araújo MA, Barros VL, et al. Complications, clinical manifestations of congenital syphilis, and aspects related to its prevention: an integrative review. Rev Bras Enferm. 2021;74:e20190318.

    2. Indexed at, Google Scholar, Cross Ref

  2. Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18(12):853-64.

    3. Indexed at, Google Scholar, Cross Ref 

  3. Furtado JM, Simões M, Vasconcelos-Santos D, et al. Ocular syphilis. Surv Ophthalmol. 2022;67(2):440-62.

    4. Indexed at, Google Scholar, Cross Ref

  4. Cordero JH, Shepard Z, Schultz J, et al. Dermatologic Manifestations of Tick-borne Diseases in Travelers. Curr Trop Med Rep. 2021;8:99-103.

    5. Indexed at, Google Scholar, Cross Ref

  5. Chen Q, Li Z, Zeng X. Diagnostic strategies for oral manifestations of infectious diseases.2021;50(2):141-7.

    6. Indexed at, Google Scholar, Cross Ref 

  6. Shieh WJ. Human adenovirus infections in pediatric population-an update on clinico–pathologic correlation. Biomed J. 2022;45(1):38-49.

    7. Indexed at, Google Scholar, Cross Ref

  7. Schwartz DM, Kitakule MM, Dizon BL, et al. Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. Ann Rheum Dis. 2021;80(6):788-95.

    8.         Indexed at, Google Scholar, Cross Ref   

  8. D?ra M, Sticová E, Felšöová A, et al. Clinical and histopathological aspects of the most common inflammatory non-infectious skin diseases. Cesk Patol. 2023;59(3):104-23.

    9.   Indexed at, Google Scholar 

  9. Quinlan JD. Human papillomavirus: screening, testing, and prevention. Am Fam Physician. 2021;104(2):152-9.

    10. Indexed at, Google Scholar

  10. Zhang M, Wang H, Tang J, et al. Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatr. 2021;21:1-2.

    11. Indexed at, Google Scholar, Cross Ref

 

Get the App